“Breakout group 2 - Life Sciences” Co-Chairs:
Toshio Miyata (Tohoku University) Malcolm Skingle (GSK)
Tuesday 10th January 2012 Building University – Business links symposium British Embassy & British Council meeting
Emerging Markets & Asia Pacific Drives GSK Growth +7% -3% ViiV £1.6bn($2.4bn)
Consumer £5.0bn ($7.3bn)
Rest of World £1.0bn($1.5bn)
+9%
+22%
US growth rate impacted by losses to generics US Pharma £7.6bn ($11.9 bn)
Japan/AP Ph £3.1bn ($4.8bn) Emerging Markets Ph £3.6bn ($5.5bn)
-11%
Europe Pharma £6.5bn ($10.2bn)
Europe growth rate impacted by losses to generics and gov’t -6% austerity measures
2010 Turnover £28.4bn/$44.0bn (-1%) CER growth rates
Criteria for selection of collaborative projects
• Strategic fit to GSK research • Quality of science in the proposal • Availability of facilities & resources • High likelihood of useful new information or technology arising • Timing with respect to deliverables • Value for money
GSK Priority areas of science • Strongly committed to academic research collaborations to • • • • • • • •
advance scientific understanding relevant to our key areas of focus: Immuno-inflammation Oncology Neurosciences Metabolic Pathways Infectious diseases Biopharmaceuticals Respiratory Ophthalmology
Process for Internal Approval of Research Collaborations • Industrial scientist discusses proposal with academic to identify areas of common interest
• Assumes role of industrial champion & discusses project with Academic Liaison
• Review project priorities with respect to resources & budget • Academic Liaison negotiate & implement agreement • Use standard agreements wherever possible
Why Collaborate ?
• Share risks & rewards • Harness other sources of funding • Access knowledge & new thinking • Build global links • Networking • Recruitment • Think longer term
GSK today – larger pipeline and much more externalized More than 80 active projects from ~50 external engines 16 new partnerships since Feb 09
Tempero Pharmaceuticals
Alveonix Pentraxin Therapeutics
Updated January 2011
UCL Institute of Ophthalmology
Alliances are delivering a partnered pipeline Percentage GSK product development pipeline from in-license or other alliance relationship with third party, by phase of development
In-house
Alliance
100% 90%
27%
80%
39%
65%
38%
Phase II
Phase III
File / Reg
Percentage
70% 60% 50% 40% 30% 20% 10% 0%
Phase I
Source: GSK Product Development Pipeline, Feb 2010, available at www.gsk.com
We are looking for innovation wherever it may originate